[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"loiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:loiasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100543052","development-of-a-new-rapid-diagnostic-test-to-support-onchocerciasis-elimination-100543052",false,"NCT06350851","Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination","Obi1","Inclusion Criteria:\n\n* Subjects informed of the objectives of the study and who signed a consent form\n* Subjects without filariasis (for control subjects), or\n* Subjects mono-infected with Onchocerca volvulus, or\n* Subjects mono-infected with Loa loa, or\n* Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Subjects having taken antihelminthic treatment less than 6 months before the inclusion date",true,"ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases. Existing diagnostic tools for onchocerciasis have limitations that make mapping, epidemiological assessments and verification of elimination of onchocerciasis difficult. It is in this context that WHO, in its 2021-2030 roadmap for onchocerciasis, has identified the development of new diagnostic tests, or the improvement of existing diagnostic tests, as a critical condition for achieving the goal of eliminating onchocerciasis transmission.\n\nTo this end, a series of cross-sectional studies will be carried out in Cameroun over a one year period to collect and characterize biological samples for the development and evaluation of a new rapid diagnostic test for onchocerciasis. The study will target individuals aged 18 and over, mono-infected with one of the filarial species Onchocerca volvulus, Loa loa or Mansonella perstans; and non-infected.\n\nAt the end of this study, data on the endemicity of onchocerciasis, loiasis and mansonellosis in the selected communities will be updated. More importantly, a new rapid diagnostic test will be developed, which can then be used to monitor the activities of onchocerciasis control programs.",[27,28,29,30],"Onchocerciasis","Loiasis","Mansonelliasis","Healthy Volunteers",[32,33,34,35,36],"Onchocerca volvulus","Loa loa","Mansonella perstans","Biplex Rapid Diagnostic Test","Neglected Tropical Diseases","RECRUITING","2025-03-05",{"date":40,"type":41},"2025-03-07","ACTUAL",{"date":43,"type":41},"2024-04-15",{"date":45,"type":21},"2025-12",{"name":47,"class":48},"Bioaster","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100563271","phase-3-21-day-double-blind-trial-of-albendazole-in-adults-with-loa-loa-microfilaremia-100563271","NCT06613997","21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia","Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 21-day Course of Albendazole 400mg\u002FDay in Subjects With High Loa Loa Microfilaremia","STOP-FiLAR-ALB","Inclusion Criteria:\n\n* Consent informed, written, signed and dated\n* Women or men aged 18 to 70 years inclusive\n* Carrier of L. loa microfilaremia\n* Body weight ≥ 40 kg and less than 90 kg\n\nExclusion Criteria:\n\n* Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of albendazole placebo)\n* Any vaccination within 4 weeks previous to this study\n* Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)\n* Known immunosuppressive pathology (by self-report)\n* Past or present history of neurological (including epilepsy) or neuropsychiatric disease\n* Current treatment with ritonavir and\u002For rifampicin\n* Use of cocaine or other drugs of abuse in the 72 hours preceding administration of the trial treatment, as determined by history during the medical interview\n* Past or present history of liver, kidney or bone marrow failure\n* ALAT transaminase level ≥ 3 times the upper limit of normal (3N) according to laboratory standards\n* Any condition, in the opinion of the investigator, that exposes the subject to undue risk\n* Known intolerance to ALB or benzimidazole derivatives in general\n* Subjects who donated blood in the previous 8 weeks to study entry, with a standard volume (500 mL)\n* On clinical examination: symptoms, physical signs or laboratory findings suggestive of systemic disorders, including disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other abnormalities that could interfere with the interpretation of trial results. The physician may then give a favorable or unfavorable opinion on the participants inclusion.\n* ALB and\u002For mebendazole in the last month\n* IVM taken in the last month\n* Any condition which, in the opinion of the investigator, exposes the subject to undue risk\n* Positive urine pregnancy test for women of childbearing age or breastfeeding","70 Years",{"count":60,"type":21},100,[62],"PHASE3","Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.",[65,28],"Loiasis With Positive Blood Microfilaremia",[67,68,27],"filariasis","Albendazole","NOT_YET_RECRUITING","2024-09-25",{"date":72,"type":41},"2024-09-26",{"date":74,"type":21},"2025-01-15",{"date":76,"type":21},"2027-12-31",{"name":78,"class":79},"Programme National de Lutte contre l'Onchocercose, Republic of the Congo","OTHER_GOV",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100535525","phase-2-a-3--to-5-day-clinical-trial-of-levamisole-in-loiasis-infected-subjects-100535525","NCT06252961","A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects","Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 3- or 5- Day Course of Levamisole 2.5 mg\u002Fkg in Subjects With Loa Loa Microfilaremia","STOP-FiLAR","Inclusion Criteria:\n\n* Consent informed, written, signed and dated\n* Women or men aged 18 to 65 years inclusive\n* Carrier of L. loa microfilaremia\n* Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 90 kg\n* In good health, as determined by medical questionnaire and general clinical examination\n* Absence of acute or chronic infection :\n\nExclusion criteria\n\n* Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of levamisole or placebo)\n* Any vaccination within 4 weeks previous to this study\n* Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)\n* Treatment with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, and gold salts: whether it was long-term treatment, or treatment given as a single dose 10 days before the start of treatment for the clinical trial (precaution with regard to the risk of agranulocytosis of immuno-allergic or toxic origin)\n* Known immunosuppressive pathology (by self-report)\n* Past or present history of neurological (including epilepsy) or neuropsychiatric disease\n* History of agranulocytosis\n* Use of cocaine or other drugs of abuse in the 72 hours preceding administration of the trial treatment, as determined by history during the medical interview\n* Any condition, in the opinion of the investigator, that exposes the subject to undue risk\n* Known intolerance to levamisole\n* Subjects who donated blood in the previous 8 weeks to study entry, with a standard volume (\\> 500 mL)\n* On clinical examination: symptoms, physical signs or laboratory findings suggestive of systemic disorders, including disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other abnormalities that could interfere with the interpretation of trial results. The physician may then give a favorable or unfavorable opinion on the participant's inclusion.\n* Ivermectin and\u002For levamisole taken in the last six months; and\u002For mebendazole or albendazole taken in the last month\n* Pregnant and\u002For breast-feeding women","65 Years",{"count":90,"type":21},99,[92,62],"PHASE2","The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg\u002Fkg) in management of loiasis microfilaremia.",[28],[27,96,97],"Filariasis","Levamisole","2024-09-18",{"date":100,"type":41},"2024-09-20",{"date":102,"type":41},"2024-06-21",{"date":104,"type":21},"2026-02-01",{"name":78,"class":79},2]